阿帕替尼治疗常规化疗失败晚期卵巢癌对患者血清CCL-18、HE4和卵巢血流的影响  

Curative Effect of Apatinib in Treatment Advanced Ovarian Cancer with Conventional Chemotherapy Failure and the Influence of Serum CCL-18,HE4 and Ovarian Blood Flow

作　　者：方军 胡继德 FANG Jun;HU Jide(Xinyang Central Hospital,Xinyang,464000)

机构地区：[1]河南省信阳市中心医院,464000

出　　处：《实用癌症杂志》2020年第4期670-673,共4页The Practical Journal of Cancer

摘　　要：目的探讨阿帕替尼治疗常规化疗失败的晚期卵巢癌对患者血清趋化因子配体18(CCL-18)、人附睾蛋白4(HE4)和卵巢血流的影响。方法选择信阳市中心医院肿瘤内三科收治的100例常规化疗失败的晚期卵巢癌患者,均采用阿帕替尼治疗。分析临床疗效,治疗前后血清CCL-18、HE4、卵巢血流、生存质量、不良反应发生情况。结果100例晚期卵巢癌患者均无完全缓解,部分缓解39例,稳定36例,进展25例,客观有效率为39.00%(39/100),疾病控制率为75.00%(75/100)。治疗后,患者血清CCL-18、HE4水平、收缩期峰值流速(PSV)均低于治疗前,搏动指数(PI)、阻力指数(RI)、共性模块及特异性模块评分均高于治疗前,比较差异有统计学意义(P<0.05)。晚期卵巢癌患者治疗后不良反应以血液毒性、腹泻、皮疹、蛋白尿、高血压及纳差乏力为主。结论阿帕替尼治疗常规化疗失败的晚期卵巢癌的近期疗效确切,能够降低血清CCL-18、HE4水平,改善卵巢血流状态,且不良反应可控。Objective To discuss the curative effect of apatinib in treatment advanced ovarian cancer with conventional chemotherapy failure and the influence of serum chemokine ligand 18(CCL-18),human epididymis protein 4(HE4)and ovarian blood flow.Methods 100 patients with advanced ovarian cancer who failed conventional chemotherapy were selected,all were treated with apatinib.Then clinical efficacy,serum CCL-18,HE4,ovarian blood flow,quality of life before and after treatment and adverse reactions occurred was analyzed.Results 100 cases of advanced ovarian cancer patients had no complete remission,39 cases was partially relieved,36 cases was stable,and 25 cases was progressed,the objective effective rate was 39.00%(39/100)and the disease control rate was 75.00%(75/100).After treatment,the serum levels of CCL-18,HE4 and peak systolic velocity(PSV)were lower than before treatment,the pulsatility index(PI),resistance index(RI),commonality module,and specificity module scores were higher than before treatmen,there was a statistically significant difference(P<0.05).the adverse reactions after treatment in patients with advanced ovarian cancer were mainly hematological toxicity,diarrhea,rash,proteinuria,hypertension and anorexia.Conclusion The short-term efficacy of apatinib in the treatment of advanced ovarian cancer with conventional chemotherapy failure is clear,can reduce serum levels of CCL-18,HE4,improve ovarian blood flow status,adverse reactions can be controlled.

关 键 词：晚期卵巢癌 阿帕替尼 常规化疗失败 疗效 趋化因子配体18 人附睾蛋白4 

分 类 号：R737.31[医药卫生—肿瘤]